Fulgent Genetics to acquire Bako Diagnostics and StrataDx for $55.5M total

Fulgent Genetics, Inc.

Acquires equity of StrataDx for $12.5M cash; asset purchase from Bako entities for $43.0M cash.
Deal expected to close in first half 2026; subject to regulatory approvals and customary conditions.
Adds anatomic pathology, proprietary PCR tests, nationwide sales team, and CLIA/CAP labs in GA and MA.
Fulgent plans to leverage AI and digital pathology (Eziopath) to improve efficiency at acquired labs.
Acquisition funded from cash on hand; Fulgent notes organic double-digit growth in lab services business.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.